Ipratropium/Salbutamol Sandoz (Salbutamol, Ipratropium Bromide Monohydrate)

Ipratropium bromide is a muscarinic antagonist that blocks acetylcholine receptors on airway smooth muscle, preventing the cholinergic-mediated constriction of the bronchi. This action reduces bronchial tone and complements the β2‑adrenergic effect of Salbutamol, resulting in additive bronchodilation.

The prescribed dose is determined by the treating physician based on the severity of the respiratory condition, patient age, and response to therapy. Typical nebuliser regimens are individualized, and the prescriber will specify the volume and frequency appropriate for each patient.

Safety data in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case and discuss alternatives when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent bronchodilators, the combination of Ipratropium and Salbutamol offers additive bronchodilation by targeting both muscarinic and β2‑adrenergic pathways. This can result in faster symptom relief and improved lung function, especially in patients who do not achieve adequate control with monotherapy.

Store the inhalation solution at room temperature, below 25 °C, in its original container. Keep the product away from direct sunlight, moisture and heat sources. Ensure the vial is tightly closed when not in use to maintain stability.

The product is supplied as a sterile solution for nebulisation. Using a compatible nebuliser, the prescribed volume is placed in the device, and the patient inhales the aerosolized mist over several minutes as directed by the healthcare professional.

Serious adverse events include paradoxical bronchospasm, significant tachycardia or arrhythmias, severe allergic reactions such as angioedema, and marked hypotension. Patients should seek immediate medical attention if they experience difficulty breathing, chest pain, rapid heartbeat, or swelling of the face or throat.

The product is contraindicated in individuals with a known hypersensitivity to Ipratropium bromide, Salbutamol, or any excipients in the formulation. Caution is advised for patients with severe cardiac arrhythmias, uncontrolled hypertension, or those taking non‑selective beta‑blockers.